|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-6-18
|
|
pubmed:abstractText |
Molecular characterization of Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor beta TKs, and is active against cells carrying the mutant KIT-D816V gene.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AkinCemC,
pubmed-author:CortesJorgeJ,
pubmed-author:FaderlStefanS,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:KantarjianHagopH,
pubmed-author:ManshouriTaghiT,
pubmed-author:O'BrienSusanS,
pubmed-author:PardananiAnimeshA,
pubmed-author:TefferiAyalewA,
pubmed-author:ThomasDeborahD,
pubmed-author:VerstovsekSrdanS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3906-15
|
|
pubmed:meshHeading |
pubmed-meshheading:18559612-Adult,
pubmed-meshheading:18559612-Aged,
pubmed-meshheading:18559612-Antineoplastic Agents,
pubmed-meshheading:18559612-Female,
pubmed-meshheading:18559612-Humans,
pubmed-meshheading:18559612-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18559612-Leukemia, Myeloid, Acute,
pubmed-meshheading:18559612-Male,
pubmed-meshheading:18559612-Mastocytosis, Systemic,
pubmed-meshheading:18559612-Middle Aged,
pubmed-meshheading:18559612-Philadelphia Chromosome,
pubmed-meshheading:18559612-Pyrimidines,
pubmed-meshheading:18559612-Remission Induction,
pubmed-meshheading:18559612-Thiazoles,
pubmed-meshheading:18559612-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
|
|
pubmed:affiliation |
Leukemia Department, M. D. Anderson Cancer Center, Houston, Texas 77030, USA. sverstov@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
